Replies to post #1211 on Ardelyx Inc (ARDX)

[Cosa]

Scripts for Ibsrela are steadily climbing and NDA for Xphozah to be submitted to FDA "early second quarter" per CEO. Its retail and institutions accumulating shares.

The proof is in the data.
Up to 49.4% of patients treated with XPHOZAH monotherapy or XPHOZAH in combination with sevelamer achieved a sP level within the normal range during the 18-month treatment period, which is 66.3% better than standard of care, at 29.7%, as shown in DOPPS February 2021
https://ir.ardelyx.com/news-releases/news-release-details/ardelyx-presents-positive-data-further-supporting-efficacy-and

This data is important. As there are many other drugs for the treatment of hyperphosphatemia. But having an additional option for patients is important. What works for some may not work for others.

Accumulation. Those bars are getting really big.